Nine Catalent Experts To Present At Annual American Association Of Pharmaceutical Scientists Meeting




Nine Catalent Experts to Present at Annual American Association of Pharmaceutical Scientists Meeting

Date: 11/02/2010

Somerset, NJ, November 2, 2010 – Leading scientists from Catalent Pharma Solutions will be presenting six scientific poster papers along with leading a mini-symposium at the Annual American Association of Pharmaceutical Scientists (AAPS) meeting (November 15-17 in New Orleans, LA) as part of the conference proceedings. At their booth (1901), Catalent will feature the Optiform™ technology, a new solid-state screening platform which can help optimize drug molecules and increase development speed. Additionally, an industry expert will present innovative and tailored solutions for today’s drug development challenges.

Scientific poster presentations include:
 o On Monday, November 15, Kieran Crowley will present “Use of Gelatin to Manufacture and Stabilize API Nanoparticles in Freeze-dried Tablets.” Authors include Deepak Bahl, Imre Vitez, and Kieran Crowley.

o On Tuesday, November 16, Sam Jones will present “Development and Validation of a Generalized Method for Determination of Extractable or Leachable Silicone Oil Content.” Authors include Sam Jones and Michelle Cree.

o On Wednesday, November 17, Dr. Norman Stroud will present “Gelatin-free softgels: compatibility studies of SEDDS and SMEDDS capsule fill formulations.” Authors include Dr. Stroud, Keith Tanner, Elizabeth Youngblood, Didier Kiyali, and Shawn McKee. Additionally on Wednesday, Dr. Rickey Shelley, author, will present “Manufacture of Phosal® MCT Softgels and Phosal® 50 PG Softgels and Stability Evaluation at Accelerated Conditions.”

o On Thursday, November 18, Irena McGuffy will present “Effect of Kollicoat Protect Top-coat on Long-Term Physical Stability of Enteric Coated Softgels.” Authors include I. McGuffy, W. Bell, and S. Tindal of Catalent with K. Zhuang and N. Langley of BASF Corporation. Also on Thursday, JJ Luo will present “Injectable Pharmaceutical Product Development for a Poorly Soluble Drug using Multiple Formulation Methodologies.” Authors include JJ Luo, Victoria Tropina, and Brian N. Woodrow.

o A mini-symposium titled "The Science and Art of Manufacturing Soft and Hard Shell Liquid-filled Capsules" will be presented by Dr. David Fulper on Thursday, November 18 at 9:00 AM.

Innovative in-booth presentations by Catalent experts will include sessions by Dr. Kurt Nielsen, Senior Vice President of Innovation & Growth, and Dr. David Igo, Director, Optiform™ Technology:

o Dr. Nielsen will provide expert insight on tailored solutions and highlight emerging industry trends for optimizing bioavailability, increasing patient adherence, and improving medication delivery. Dr. Nielsen's presentation, “Innovative Solutions for Today’s Drug Development Challenges” will take place on Monday, November 15 at 2:00 PM.

 o Dr. Igo will outline how utilizing Catalent’s new Optiform™ technology can help discover and select optimal salts and crystal-forms to successfully navigate compounds from early development through product launch. Dr. Igo will present “OptiformTM Technology – A Fit-for-Purpose Solution to Solid-State Issues” on Tuesday, November 16 at 2:30 PM. The presentation will be followed by a question and answer session and a chance to meet Dr. Igo at a cocktail reception beginning at the booth at 3:00 PM. Dr. Igo will make a repeat performance on Wednesday, November 17 at 11:00 AM.

To schedule an interview with any of the above-mentioned presenters, during AAPS or after, please contact Patricia McGee at media@catalent.com .

To receive a copy of any presentation after the event, contact Holly Rackett at holly.rackett@catalent.com .

For more information on Catalent at AAPS, visit www.catalent.com/aaps2010

About Catalent

Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 people at 29 facilities worldwide and in fiscal 2010 generated more than $1.7 billion in annual revenue. For more information, visit www.catalent.com .

more products. better treatments. reliably supplied.™

PHOSAL is a registered trademark of Phospholipid GmbH.